Stock of the Day

March 18, 2024

Teladoc Health (TDOC)

$6.35
-$0.15 (-2.3%)
Market Cap: $1.18B

About Teladoc Health

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

Today's Trend

Teladoc Health, Inc. (NYSE: TDOC) shares have decreased as investors weigh mixed earnings-estimate revisions against a new investor investigation.

  • Zacks Research improved several profit forecasts. The firm raised its FY2026 EPS estimate to a loss of $0.89 from $0.96 and its FY2027 estimate to a loss of $0.98 from $1.04. Estimates also improved for Q4 2026, Q1–Q3 2027, and Q1 2028, suggesting somewhat better expected profitability than previously projected.
  • The overall outlook remains challenging. Despite the upward revisions, Zacks still expects Teladoc to remain unprofitable through FY2027, with consensus calling for a $0.89-per-share loss in the current year. The firm lowered its Q3 2026 estimate to a $0.21 loss from $0.20 and its Q2 2028 estimate to a $0.21 loss from $0.20, partially offsetting the positive revisions.
  • Pomerantz LLP announced an investor investigation into Teladoc. The law firm is seeking information from investors regarding potential claims on behalf of shareholders. Such announcements can pressure a stock by increasing legal and reputational uncertainty, although the investigation does not establish wrongdoing by Teladoc. Pomerantz investor investigation announcement

The estimate changes provide a modestly favorable signal for TDOC’s cost-control and earnings trajectory, but the continued expectation of losses and the investor investigation likely explain why sentiment remains weak. Teladoc’s latest reported quarter also showed revenue declining 4% year over year, reinforcing concerns about growth.

Teladoc Health gaps down to support level after weak guidance

Written By Chris Markoch on 2/21/2024

Teledoc stock price

One of 2021's favorite meme stocks is falling on hard times. Teladoc Health Inc. (NYSE: TDOC) stock is down more than 22% in early morning trading after the company delivered a poor outlook for 2024.  

Teladoc generated $660.50 million in revenue for the fourth quarter, a 4% year-over-year (YOY) improvement. The company's negative loss per share of 17 cents was also better than the negative 23 cents per share in the fourth quarter of 2022.  

But that was about as good as it got. The company posted weak guidance with projections for low single-digit growth in subscriber growth and revenue. And the company will continue to be unprofitable throughout 2024. 

One comment that should bother the bulls 

On balance, Teladoc didn't deliver an awful report. But it's not a profitable company, and its business model relies on being able to grow its customer base. That's why one comment on the company's earnings call stood out.  

Chief executive officer Jason Gorevic said, "...it's important to remember that most US healthcare consumers have access to virtual urgent care today. So, it's largely a replacement market at this point." 

The takeaway is that, at least for one market segment, the company will have to fight hard to win customers. This is at a time when Teladoc is trying to cut its acquisition costs to become profitable. To that end, Gorevic predicted that revenue growth for the company's virtual care products in the United States would be in the low single digits. 

More tools in its toolkit 

The counterargument from the bulls would be that Gorevic's comment was only regarding chronic and urgent care. But Teladoc launched its BetterHelp service for mental health. The company also plans to expand its specialty wellness offerings to include weight management and pediatric care.  

As Teladoc correctly notes, demand for mental health services exceeds supply. And the nature of mental health makes virtual care a preferable option.  

That said, investors were closely watching the subscriber count and revenue from BetterHelp. They were disappointed. BetterHelp did deliver double-digit adjusted EBITDA growth for the quarter and the full year. However, revenue and margins fell below the company's expectations.  

You have to spend money to make money. However, at least for now, that's not showing up in Teladoc's numbers. And it's not likely to for several quarters.  

Why Teladoc may still be worth watching 

TDOC stock knifed below its 50- and 200-day simple moving averages. At around $15.50 as of this writing, the stock is at a key support level that it hit in late October 2023 and again in November 2023. But that sell-off may be overdone.  

The Teladoc analyst ratings on MarketBeat show one analyst, Canaccord Genuity Group, lowered its price target from $32 to $26 but reiterated its Buy rating. That suggests that analysts needed a reason to sell TDOC stock, and they got it.  

As I mentioned at the start of this article, Teladoc was one of the popular meme stocks. It went public in 2019 and caught lightning in a bottle from a global pandemic that provided a powerful use case for virtual care. Needless to say, investors aren't valuing the stock as one of the top technology stocks. Except maybe Cathie Wood. That remains to be seen.  

Nevertheless, institutions may still see value ... at the right price or as an acquisition target. And a $26.60 price target is a 29% gain. That's why it may still belong on your watchlist.  

Still, right now, TDOC stock may be a better trade. Short interest is at 11.6%, and I imagine it will increase as many traders buy put options. That's a lot of selling pressure. But it's also fuel for a squeeze if the company can hit its lowered expectations.  

Recent News